Drug intelligence / Profile preview

mAb127

Development stage: Preclinical
Lead developer: LeafBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

mAb127 is a monoclonal antibody being developed by Mapp Biopharmaceutical and its commercial subsidiary, LeafBio, for the intramuscular (IM) prophylaxis of Monkeypox. The antibody is designed to provide passive immunity by neutralizing the Monkeypox virus, potentially preventing infection or mitigating disease severity following exposure. Currently in the IND-enabling phase, mAb127 represents a targeted therapeutic approach to managing orthopoxvirus outbreaks, specifically focusing on providing protection to individuals at high risk of infection.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)ACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on mAb127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb127.

Explore the full profile